N-myristoyltransferases inhibitory activity of ellagitannins from Terminalia bentzoë (L.) L. f. subsp. bentzoë.

@article{Apel2018NmyristoyltransferasesIA,
  title={N-myristoyltransferases inhibitory activity of ellagitannins from Terminalia bentzo{\"e} (L.) L. f. subsp. bentzo{\"e}.},
  author={C. Apel and J. Bignon and M. C. Garcia-Alvarez and S. Ciccone and P. Clerc and I. Grondin and E. Girard-Valenciennes and J. Smadja and P. Lopes and M. Fr{\'e}d{\'e}rich and F. Roussi and T. Meinnel and C. Giglione and M. Litaudon},
  journal={Fitoterapia},
  year={2018},
  volume={131},
  pages={
          91-95
        }
}
  • C. Apel, J. Bignon, +11 authors M. Litaudon
  • Published 2018
  • Chemistry, Medicine
  • Fitoterapia
  • N-myristoylation (Myr) is an eukaryotic N-terminal co- or post-translational protein modification in which the enzyme N-myristoyltransferase (NMT) transfers a fatty acid (C14:0) to the N-terminal glycine residues of several cellular key proteins. Depending on the cellular context, NMT may serve as a molecular target in anticancer or anti-infectious therapy, and drugs that inhibit this enzyme may be useful in the treatment of cancer or infectious diseases. As part of an on-going project to… CONTINUE READING
    3 Citations

    References

    SHOWING 1-10 OF 36 REFERENCES
    Recent Advances in The Discovery of N‐Myristoyltransferase Inhibitors
    • 24
    Protein N-myristoylation.
    • 204
    Protein N-myristoylation as a chemotherapeutic target for cancer.
    • 37
    • PDF
    Protein myristoylation in health and disease
    • 171
    Antifungals targeted to protein modification: focus on protein N-myristoyltransferase
    • 55
    Inhibition of protein N-myristoylation: a therapeutic protocol in developing anticancer agents.
    • 20